FDA
-
-
-
-
-
-
-
Soligenix halts phase 3 trial of HyBryte for lymphoma treatment
-
-
-
-
-
-
-
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
-
-
-
-
-
-
-
Soligenix to Present at BIO Investment & Growth Summit
-
-
-
-
-
-
-
NetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease
-
-
-
-
-
-
-
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
-
-
-
-
-
-
-
Soligenix expands European medical board for lymphoma drug approval push
-
-
-
-
-
-
-
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

